TY  - GEN 
AU  - García-Muñoz, R.
AU  - Quero, C.
AU  - Pérez-Persona, E.
AU  - Domingo-García, A.
AU  - Pérez-López, C.
AU  - Villaescusa-de-la-Rosa, T.
AU  - MARTINEZ CASTRO, ANA MARGARITA
AU  - Arguiñano-Pérez, J. M.
AU  - Parra-Cuadrado, J. F.
AU  - Panizo, C.
PY  - 2020
SN  - 0007-1048
UR  - http://hdl.handle.net/20.500.11940/16775
AB  - Rituximab is a standard treatment for non-Hodgkin diffuse large B-cell (DLBCL) and follicular (FL) lymphomas. A subcutaneous formulation was developed to improve the resource use of intravenous rituximab, with comparable efficacy and safety profiles...
KW  - Adult
KW  - Middle Aged
KW  - Humans
KW  - Disease-Free Survival
KW  - Adolescent
KW  - Lymphoma
KW  - Survival Rate
KW  - Aged
TI  - Safety of switching from intravenous to subcutaneous rituximab during first-line treatment of patients with non-Hodgkin lymphoma: the Spanish population of the MabRella study
DO  - 10.1111/bjh.16227
KW  - CHUVI
VL  - 188
ER  -